Lymphoma

The European Hematology Association (EHA) 2026 Congress brought together the global hematology community to unveil the latest practice-shaping advances in hematological malignancies and blood disorders. From plenary and late-breaking trial results to prestigious award winners, novel therapeutics, translational science and emerging technologies, the meeting delivered a vast volume of data. In this expert-led round-up, leading specialists distil the most important data and key takeaways from across each disease area, offering an essential guide to the studies set to shape the future of hematology.

At EHA 2026, Erik Aerts, President of the hematology Nurses & Healthcare Professionals Group, highlighted the dual pressures shaping hematology nursing: rapidly increasing treatment complexity and a growing workforce shortage across Europe. He outlined how HNHCP is responding through expanded education, new learning programmes in AML, ALL and MPNs, and stronger international collaboration to support nurses in an evolving therapeutic landscape.

At the European Hematology Association Congress 2026, the phase 3 BRUIN CLL-322 trial showed that fixed-duration Pirtobrutinib plus Venetoclax–Rituximab significantly improved progression-free survival versus venetoclax–rituximab alone in relapsed/refractory Chronic lymphocytic leukemia/Small lymphocytic lymphoma, with higher undetectable MRD rates and similar safety. Speaking after his presentation, Dr Matthew Davids said the findings could help establish a new fixed-duration standard of care in relapsed disease.

New data presented at EHa 2026 by Prof Yizhen Li identify CD5 as a key intrinsic regulator of T-cell engager (TCE) efficacy, with potential implications across both hematologic malignancies and solid tumors. In the plenary abstract, investigators used genome-wide and targeted CRISPR knockout screens in primary human CD8+ T cells exposed to the CD19×CD3 bispecific Blinatumomab to identify T cell–intrinsic mechanisms limiting response. Importantly, the effect extended beyond B-ALL to multiple CD3-engaging bispecifics targeting CD20, BCMA, GPRC5D, DLL3, and GD2, supporting CD5 as a potentially generalizable therapeutic target for amplifying TCE efficacy.

For almost two decades, R-CHOP has remained the established frontline standard for DLBCL, yet approximately 40% of patients are not cured with first-line therapy. At EHA 2026, Prof Georg Lenz presented new phase 3 data from the frontMIND study suggesting that this long-standing backbone may now be open to improvement. The study showed that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival (PFS) in previously untreated patients with high-risk DLBCL and high-grade B-cell lymphoma (HGBL), marking one of the first positive frontline intensification trials in this setting in recent years.

Several important lymphoma studies presented at ASCO 2026 provided new data across newly diagnosed and relapsed/refractory disease settings. The studies spanned aggressive B-cell lymphomas and classic Hodgkin lymphoma, evaluating novel antibody-based combinations, epigenetic targeting strategies and chemotherapy-sparing approaches. Dr Tycel Phillips provides his expert insights into the six most important studies of the meeting.

2025 has brought exciting developments in haematology, with groundbreaking research and real-world progress showcased at EHA, ASH, EBMT and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.

The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.

Discover the practice-changing data shaping the future of myeloma, chronic lymphocytic leukemia and small lymphocytic lymphoma. Our ASH25 coverage highlights the pivotal Majestec-3 results, emerging CAR T-cell innovations, and the landmark BRUIN CLL-313 trial poised to redefine first-line therapy. With expert commentary from Prof. Meletios-Athanasios Dimopoulos, this in-depth analysis uncovers what these breakthroughs mean for clinical practice.